Management Team

Robert Habib MBA

Chief Executive Officer

Robert joined MiNA as Chief Executive Officer and first employee in 2013. In that period he has been the driving force in establishing MiNA’s strategy, therapeutic platform, IP portfolio and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and an MBA from Columbia Business School.

David Blakey PhD

Chief Scientific Officer

David joined MiNA in 2015 as Chief Scientific Officer and has been leading MiNA’s internal and external R&D efforts. David has over 25 years of drug discovery and development experience and is an industry leader in the development of oligonucleotide therapeutics. Prior to joining MiNA David held multiple roles at AstraZeneca, mostly recently Chief Scientist in Oncology. David holds a PhD from MRC Laboratories in Drug Metabolism and Toxicology and is a Director of the Oligonucleotide Therapeutics Society.

David Collin MSc

Director of Clinical Operations

David Collin joined MiNA in 2015 as Director of Clinical Operations to manage our clinical research efforts. David has over 10 years of hands-on clinical development experience at University College London, Sarah Cannon Research Institute, Sanofi Pasteur and Novartis. David has expertise in first-in-human clinical trials in translational medicine and holds an MSc in Clinical Operations & Data Management from the University of Montpellier.

Board of Directors

Professor Nagy Habib MD, ChM, FRCS

Chairman and Co-Founder

Nagy is currently Lead Clinician and Head of the Department of HPB Surgery at Imperial College London. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery.

Peter Bains

Non Executive Director

Peter has more than two decades of experience in the global pharmaceutical space and is currently Chief Executive Officer and Director of Sosei Group and Director of Mereo BioPharma. Peter has held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies.

Chris Wood MD, FRCS

Non Executive Director

Chris has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited four companies including Bioenvision and Medirace. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School. Chris is currently Executive Chairman of NuCana BioMed and Edixomed.

Robert C. Kopple JD, LLM

Non Executive Director

Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors of several biotechnology companies including Hibernation Therapeutics and Bioseal.

Robert Habib MBA

Chief Executive Officer

Robert joined MiNA as Chief Executive Officer and first employee in 2013. In that period he has been the driving force in establishing MiNA’s strategy, therapeutic platform, IP portfolio and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and an MBA from Columbia Business School.

Scientific Advisory Board

Professor John Rossi PhD

Co-Founder

John is Dean of the Irell and Manella Graduate School of Biological Sciences at City of Hope’s Beckman Research Institute. He is a pioneer in the field of molecular genetics and in particular small RNA. John is Scientific Co-Founder of Dicerna Pharmaceuticals and co-inventor of its Dicer Substrate Technology. John founded Calando Pharmaceuticals, a wholly owned subsidiary of Arrowhead Research Corporation.

Professor Pål Sætrom MSc, DPhil

Co-Founder

Pål is Head of the Algorithms, HPC and Graphics Research Group at the Norwegian University of Science and Technology. He develops and applies predictive computational models to gene regulation in a disease setting. Pål is Co-Founder of Interagon AS.

Declan Doogan MD, FRCP

Declan is Chairman of Biohaven Pharmaceuticals, CEO of Portage Biotech and Non-Executive Director of Sosei Group. He has more than 30 years of pharmaceutical industry experience spanning numerous roles including Chairman of Spinifex Pharmaceuticals, Chief Medical Officer at Amarin Corporation and Senior Vice President and Head of World Development at Pfizer. Declan is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received his Medical degree from Glasgow University.

Hans Huber PhD

Hans is Principal of BioTD Strategies, LLC, where he advises biotechnology companies and life science investors on preclinical development strategy and evaluation of targeted drug delivery and RNA therapeutics programs and technologies. In addition, Hans is an Adjunct Associate Professor of Systems Pharmacology and Translational Therapeutics and Associate Director of The Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. Previously, Hans held multiple roles in preclinical R&D at Merck & Co., Inc, most recently Distinguished Senior Investigator, RNA Therapeutics. Hans received his PhD in Biochemistry at the ETH Zurich and was a research fellow at Harvard Medical School.

Antonin de Fougerolles PhD

Antonin is Chief Scientific Officer of Ablynx, a role he has held since 2013. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Moderna Therapeutics, Chief Scientific Officer of Tolerx and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.